Dana17
- ViAqua Therapeutics, an Israeli-based biotechnology startup, has secured $8.25 million in funding for its oral RNA-based shrimp vaccine
- The vaccine targets white spot syndrome virus (WSSV), which leads to a 15% reduction in global shrimp production each year
- ViAqua plans to administer its RNA-based product via coated feed; the RNA molecules can inhibit gene expression, silencing disease-affected genes
- Shrimp lack an adaptive immune system, the type that “remembers” exposures to infectious agents, so it’s long been assumed that shrimp cannot be vaccinated; now it’s becoming clear that shrimp do have some defense against viruses, which is only beginning to be understood
mRNA Vaccines Now Headed for Shrimp (articles.mercola.com)
